CTOs on the Move

Immunocellular Therapeutics (Fka: Optical Molecu

www.imuc.com

 
Immunocellular Therapeutics Ltd (Fka: Optical Molecular Imaging Inc) is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.imuc.com
  • 21900 Burbank Blvd Fl 3
    Woodland Hills, CA USA 91367
  • Phone: 818.992.2907

Executives

Name Title Contact Details

Similar Companies

Exothera

Exothera is a CDMO delivering customized process development and GMP production services for viral vectors in Belgium

Omicia

Omicia is unlocking the potential of individualized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from personal genome sequences, to improve disease management and medical outcomes. Researchers and clinical diagnostic organizations use our solutions to analyze and identify the genetic basis of a variety of conditions, including childhood disease, cancer and cardiovascular disease. Opal™, the leading platform for fast, accurate and flexible genome analysis, enables clinicians, researchers and bioinformaticians alike to derive clinically relevant insights from genomic data. VAAST, our robust novel disease gene finder and variant scoring algorithm, is in use at more than 300 academic and clinical institutions including the NIH, the University of Oxford, the University of Cambridge, Seattle Children’s Research Institute, Institut Pasteur, University of Maryland Institute for Genome Sciences, and UCSF.

SangStat Medical Corporation

SangStat Medical Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immuneering

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering`s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering`s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.

BH1 (Better Health for Everyone)

BH1 (Better Health for Everyone) is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.